Outcomes in patients with BRAF^V600-mutated melanoma and brain metastases at baseline treated with dabrafenib plus trametinib.

ABSTRACT:

Background

Brain metastases (BM) and lactate dehydrogenase (LDH) levels above the upper limit of normal (ULN) are associated with poor prognosis in patients with melanoma. Although treatment with the BRAF inhibitor dabrafenib and the MEK inhibitor trametinib have demonstrated long-term clinical benefit in patients with melanoma, data on their efficacy in patients with BM are limited.

Methods

DESCRIBE Italy is an observational, retrospective, real-world study evaluating dabrafenib plus trametinib in 499 patients with BRAF^V600-mutant stage III unresectable or stage IV melanoma from various sites across Italy. Here, we analyzed the clinical outcomes for the subgroup of patients receiving first-line treatment and presenting with BM at diagnosis and assessed the

SUBMITTER: Aglietta M 

PROVIDER: S-EPMC10702308 | biostudies-literature | 2023 Dec

REPOSITORIES: biostudies-literature